Mapping the genome in 3D to reveal new drug targets
Find out how a three-dimensional view of the genome is giving scientists a clearer picture of disease biology and revealing new opportunities for targeted therapies.
List view / Grid view
Find out how a three-dimensional view of the genome is giving scientists a clearer picture of disease biology and revealing new opportunities for targeted therapies.
Zasocitinib is a highly selective, investigational TYK2 inhibitor developed to target immune-mediated diseases with fewer off-target effects than traditional JAK inhibitors. This article explores its mechanism, selectivity data and clinical progress.
Scientists in Singapore have discovered that gut support cells – known as telocytes – use neuron-like extensions to deliver signals directly to intestinal stem cells. This could lead to new treatments for diseases such as inflammatory bowel disease and colon cancer.
Scientists have found a key mechanism driving immune regulation in autoimmune diseases like MS and IBD – which could lead to new targeted treatments.
Discover how Domain Therapeutics is using its deep knowledge of GPCR biology to create novel therapeutics with the potential to combat inflammatory diseases such as atopic dermatitis, IBD and arthritis.
We had the privilege of speaking to Dr Mark R. Kelley, Associate Director of Basic Science at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, and Betty and Earl Herr Professor in Pediatric Oncology Research, prior to his talk at PharmSci 360 in 2024. He elucidates what makes…
Intestinal epithelial organoids highlight a pathway implicated in CD, named major histocompatibility complex (MHC)-I.
Researchers have identified a new biological pathway driving IBD and similar conditions that could be targeted with MEK inhibitors.
Through in vitro and in vivo models, researchers find a mechanism by which bacteria-generated fatty acids regulate immune responses.
A new approach called reverse metabolomics has discovered molecules that may serve as a biomarker or a therapeutic target for IBD.
A technique that can sort millions of CRISPR-edited cells based on their secretion patterns has been developed to treat autoimmune diseases.
Researchers have developed organoids with naturally occurring early-stage immune cells, which could lead to effective personalised treatment.
An increasing number of people worldwide suffer from inflammatory bowel disease (IBD). However, no treatment is effective for all patients. In this article, researchers working on the Algae4IBD project explain how algae may represent a valuable source of prebiotics and new therapeutic agents for IBD and other diseases.
New research from Cincinnati Children’s Hospital Medical Center suggests blocking IL-22 and IL-1R could offer a promising IBD treatment.
Researchers from the University of Pennsylvania have developed a novel organ-on-a-chip technology called OCTOPUS, an optimised device for growing mini-organs in a dish.